These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16887605)

  • 21. In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
    Finegold SM; John SS; Vu AW; Li CM; Molitoris D; Song Y; Liu C; Wexler HM
    Anaerobe; 2004 Aug; 10(4):205-11. PubMed ID: 16701520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel biaryl oxazolidinones: in vitro and in vivo activities with pharmacokinetics in an animal model.
    Barman TK; Pandya M; Mathur T; Bhadauriya T; Rao M; Khan S; Singhal S; Bhateja P; Sood R; Malhotra S; Das B; Paliwal J; Bhatnagar PK; Upadhyay DJ
    Int J Antimicrob Agents; 2009 Mar; 33(3):280-4. PubMed ID: 19091517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Linezolid: antibacterial activity, clinical efficacy and resistance].
    Bourgeois-Nicolaos N; Piriou O; Butel MJ; Doucet-Populaire F
    Ann Biol Clin (Paris); 2006; 64(6):549-64. PubMed ID: 17162258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibacterial activity of YC-20, a new oxazolidinone.
    Cui Y; Dang Y; Yang Y; Zhang S; Ji R
    J Antimicrob Chemother; 2006 Aug; 58(2):452-4. PubMed ID: 16807251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
    Biedenbach DJ; Jones RN
    J Clin Microbiol; 1997 Dec; 35(12):3198-202. PubMed ID: 9399519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Activity of fusidic acid on strictly anaerobic bacteria].
    Canzi AM; Weber P; Boussougant Y
    Pathol Biol (Paris); 1987 May; 35(5):577-80. PubMed ID: 3302863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of four frog skin-derived antimicrobial peptides (temporin-1DRa, temporin-1Va and the melittin-related peptides AR-23 and RV-23) against anaerobic bacteria.
    Urbán E; Nagy E; Pál T; Sonnevend A; Conlon JM
    Int J Antimicrob Agents; 2007 Mar; 29(3):317-21. PubMed ID: 17196372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci.
    Citron DM; Kwok YY; Appleman MD
    Anaerobe; 2005; 11(1-2):93-5. PubMed ID: 16701537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. United States resistance surveillance results for linezolid (LEADER Program for 2007).
    Jones RN; Ross JE; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
    Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
    Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.
    Shinabarger DL; Marotti KR; Murray RW; Lin AH; Melchior EP; Swaney SM; Dunyak DS; Demyan WF; Buysse JM
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2132-6. PubMed ID: 9333037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity of some Australian plant species from the genus Eremophila.
    Ndi CP; Semple SJ; Griesser HJ; Barton MD
    J Basic Microbiol; 2007 Apr; 47(2):158-64. PubMed ID: 17440918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents.
    Takhi M; Singh G; Murugan C; Thaplyyal N; Maitra S; Bhaskarreddy KM; Amarnath PV; Mallik A; Harisudan T; Trivedi RK; Sreenivas K; Selvakumar N; Iqbal J
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5150-5. PubMed ID: 18768315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The post-antibiotic effects of linezolid against Gram-positive pathogens.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
    Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial susceptibility of 800 anaerobic isolates from patients with dentoalveolar infection to 13 oral antibiotics.
    Kuriyama T; Williams DW; Yanagisawa M; Iwahara K; Shimizu C; Nakagawa K; Yamamoto E; Karasawa T
    Oral Microbiol Immunol; 2007 Aug; 22(4):285-8. PubMed ID: 17600542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
    Jones RN; Biedenbach DJ; Anderegg TR
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):119-22. PubMed ID: 11858907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.